Hyperinsulinaemic hypoglycaemia (HH), which causes persistent neonatal hypoglycaemia, can result in neurological damage and it's management is challenging. Diazoxide is the first-line treatment, albeit not all patients will fully respond to it, as episodes of hypoglycaemia may persist and it entails unpleasant adverse effects. Sirolimus, an mTOR inhibitor, has reportedly been successful in treating children with severe diffuse HH, thus obviating the need for pancreatectomy. We report a girl with HH, with a novel heterozygous ABCC8 gene missense mutation (c.4154A>T/ p.Lys1385Thr), who was initially responsive to diazoxide therapy. After 11 months of diazoxide treatment, she developed intermittent, unpredictable breakthrough episodes of hypoglycaemia, in addition to generalized hypertrichosis and weight gain from enforced feeding to avoid hypoglycaemia. Sirolimus, which was commenced at 15 months of age, gradually replaced diazoxide, with significant reduction and abolition of hypoglycaemia. The hypertrichosis resolved and there was less weight gain given the reduced need for enforced feeding. Sirolimus, which was administered over the next 15 months, was well tolerated with no significant side effects and was gradually weaned off. After stopping sirolimus, apart from hypoglycaemia developing during an episode of severe viral gastroenteritis, the capillary glucose concentrations were maintained >3.5 mmol/L, even after a 10 h fast. Sirolimus may have a role in the treatment of partially diazoxide-responsive forms of HH who experience breakthrough hypoglycaemia, but the long-term safety and efficacy of sirolimus are not established.
Background
Hyperinsulinaemic hypoglycaemia (HH) from dysregulated insulin secretion of the pancreatic β-cells is an important cause of persistent neonatal hypoglycaemia. Mutations have been reported in the ABCC8 and KCNJ11 genes on chromosome 11p15.1, which encode the sulphonylurea receptor 1 (SUR1) and the inward rectifying potassium channel (Kir6.1) proteins, respectively (1) . Both these proteins constitute the ATP-sensitive plasma membrane potassium (KATP) channel, the regulation of which controls cell membrane polarization, which determines insulin release from the pancreatic β-cell. Inactivating mutations of the ABCC8 and KCNJ11 genes result in closure of the KATP channels, leading to depolarization of the cell membrane, opening of the voltage-dependent calcium channels and insulin release. Diazoxide has been the conventional firstline treatment of diffuse HH as it opens the KATP channel and inhibits insulin secretion. However, diazoxide is associated with unpleasant side effects including fluid retention, blood dyscrasias, nausea and hypertrichosis.
The use of sirolimus, an inhibitor of mTOR (the mammalian target of rapamycin) as an immunosuppressant in post-renal transplant patients uncovered its association with hyperglycaemia (2) . Studies of the pancreas in patients with diffuse HH suggest a pathogenic role in overexpression of the mTOR pathway (3) . Research has demonstrated that sirolimus can effectively suppress β-cell proliferation and reduce the severity of HH. Inhibitors of mTOR have already been successfully used to treat adults with pancreatic insulin secreting tumours (4) .
In recent reports, sirolimus was efficacious and safe in children with HH who were unresponsive to diazoxide therapy and octreotide, thus obviating the need for near total pancreatectomy (5). We report a 3-year 3-monthold girl who demonstrated initial partial response to diazoxide, but then developed intermittent, unpredictable hypoglycaemic episodes and severe hypertrichosis with weight gain. Sirolimus, which replaced diazoxide, was successfully used in abolishing hypoglycaemia and resolving the diazoxide-associated side effects. Shortly after stopping sirolimus, the blood glucose levels remained in the normal range, except during the stress of a viral illness.
Case report
A Chinese girl was born at 36 weeks gestation by normal vaginal delivery, with a birth weight of 3.8 kg (+2.1 s.d.). She was hypoglycaemic within the first 3 h of life, with a capillary blood glucose level of 1.6 mmol/L. She subsequently developed recurrent episodes of non-ketotic hypoglycaemia requiring an intravenous 12.5% dextrose drip with a maximal dextrose concentration of 8 mg/kg/min and boluses of intravenous glucagon.
Investigations performed when she was hypoglycaemic with a serum glucose level of 0.6 mmol/L (11 mg/dL) demonstrated an inappropriately elevated serum insulin concentration of 9.4 U/L, with a normal serum cortisol level of 427 nmol/L, a normal growth hormone concentration of 54.6 U/L and a normal metabolic screen. The clinical and biochemical diagnosis of HH was made. She was then commenced on oral diazoxide and transferred to our hospital at day 8 of life for continued management.
On initial assessment, she was plethoric, well thrived with mild facial hypertrichosis. Her tone was normal, with a normal Moro reflex. Over the next 3 weeks, she required increasing doses of diazoxide, reaching a maximum dose of 20 mg/kg/day, so as to maintain normoglycaemia. Hydrochlorothiazide, which has a synergistic effect in suppressing insulin secretion, was added to prevent fluid retention. She did not require further escalation of treatment to octreotide, glucagon or nifedipine. Concurrently, the glucose infusion rate was decreased as she was weaned to full feeds providing 106 cal/kg/day, with the addition of glucose polymers and cornstarch. Her initial response to diazoxide allowed her to be discharged with capillary glucose levels above 3.5 mmol/L and a fasting duration of 6 h.
She was subsequently followed up at the paediatric endocrine specialist clinic. She experienced no hypoglycaemic episodes and was weaned off glucose polymers and cornstarch with a gradual reduction of diazoxide to a minimum dose of 9 mg/kg/day at 4 months of age. However, the frequency of intermittent borderline hypoglycaemic episodes (lowest capillary glucose level of 2.5 mmol/L) increased to an average of twice a week from 6 months of age, necessitating a gradual increase in the diazoxide dose to 11.7 mg/kg/day.
Genomic DNA was extracted from peripheral blood leucocytes from the infant and both clinically unaffected parents using standard procedures and sent to the molecular genetics laboratory at the University of Exeter Medical School for analysis of mutations in the ABCC8 and KCNJ11 genes. This confirmed that the infant was heterozygous for a novel missense mutation in the ABCC8 gene (c.4154A>T/p.Lys1385Thr). Since the lysine residue is highly conserved, this mutation is very likely to be pathogenic. Analysis of both parents demonstrated that the mutation arose de novo and originated from the paternal copy of the ABCC8 gene. Given the genetic finding, in order to exclude a focal lesion, the child subsequently had an 18 F-Fluoro-l-DOPA positron emission tomography scan, which confirmed that she had the diffuse form of HH.
Subsequently, the intermittent breakthrough episodes of hypoglycaemia led to an increase in the diazoxide dose to 12.6 mg/kg/day associated with progressive worsening of diffuse hypertrichosis over the whole body including her face, trunk and limbs. Her appetite was poor and hence, if hypoglycaemic, required forced feeding, which led to excessive weight gain. The option of octreotide was discussed with both parents. Since octreotide is administered as a parenteral injection several times a day, with the possibility of tachyphylaxis, the parents were keen to proceed with a trial of oral sirolimus, even though the long-term side effects were not known. At 15 months of age, in view of the intermittent and persistent episodes of hypoglycaemia, she was commenced on oral sirolimus at a dose of 0.1 mg tds (0.5 mg/m 2 /day), which was titrated to achieve a target level between 5 and 15 ng/mL with regular monitoring of her full blood count, liver and renal function tests. The sirolimus trough level was checked monthly and the dose was titrated upwards to 1.0 mg tds (4.4 mg/m 2 / day), which eventually maintained the serum sirolimus trough level between 25 and 30 ng/mL, with abolition of hypoglycaemia. The diazoxide dose was concurrently decreased and stopped 3 months after starting sirolimus.
Sirolimus was well tolerated and the hypertrichosis resolved. She was feeding significantly better and the frequency of feeds was reduced, as her capillary glucose levels were generally above 4-5 mmol/L. This resulted in less weight gain. However, she developed oral ulcers with clinically insignificant elevations in the serum CK to a maximum of 694 U/L (normal range: 20-300 U/L) and ALT levels to a maximum of 83 U/L (20-65).
After 15 months of treatment with sirolimus, she was able to maintain her capillary glucose levels >4 mmol/L for progressive longer periods of time and the borderline hypoglycaemic episodes only occurred when she was unwell with poor feeding and vomiting. As her capillary glucose levels were stable with no hypoglycaemic episodes, she was weaned off sirolimus over the next 6 months. There were no hypoglycaemic episodes when the sirolimus dose was tapered and her capillary glucose levels remained consistently >4 mmol/L. However, 1 month after stopping sirolimus, she developed a bout of viral gastroenteritis and was hospitalized for 5 days with severe vomiting, watery diarrhoea and poor feeding. Her lowest serum glucose level was 2.5 mmol/L and she was started on a 10% dextrose drip to maintain normoglycaemia. When she started to feed again, her blood glucose levels were maintained >4.0 mmol/L, the dextrose drip was stopped and she was discharged well. At her most recent outpatient visit, she was 3 years 3 months of age and her developmental milestones were normal. She was able to maintain her capillary glucose levels >3.5 mmol/L, even after 10 hours fasting. Both the serum CK and ALT levels normalized after stopping sirolimus.
Discussion
The management of diffuse HH to prevent recurrent hypoglycaemia and brain damage is very challenging. Conventional treatments including the use of diazoxide, octreotide and nifedipine are not always able to prevent hypoglycaemic episodes and are often associated with unpleasant side effects. Historically, severe cases of diffuse hyperinsulinism, which did not respond to medical treatment required near total pancreatectomy, result in diabetes mellitus and exocrine pancreatic insufficiency, with possible persistent hypoglycaemia after surgery. Recently, the use of sirolimus was introduced as a potential effective alternative medical treatment for congenital hyperinsulinism. The mTOR signalling pathway promotes β-cell growth, islet size and insulin production. This pathway is crucial for β-cell function and glycaemic control (6) . The inhibition of the mTOR pathway by sirolimus can potentially cause suppression of β-cell proliferation and reduce hyperinsulinism. This is the first report of successful treatment with sirolimus in a partially diazoxide-responsive HH child. Initial treatment with diazoxide resulted in a significant improvement in the capillary glucose levels and the child could be discharged from hospital on oral feeds. Not unexpectedly, there were occasional breakthrough episodes of mild hypoglycaemia not requiring any further admissions or escalation in therapy, which was in keeping with sudden surges of insulin release, as a consequence of the inactivating mutations of the sulphonylurea receptor. However, the diazoxide-associated side effects including poor appetite, excessive weight gain from overfeeding to treat hypoglycaemia and generalized hypertrichosis were very distressing for the family.
After conversion to sirolimus, there was significant improvement with complete resolution of hypoglycaemia when the trough sirolimus levels ranged from 25 to 30 µg/L. This was higher than the original trough sirolimus level of 5-15 ng/mL, as reported by Seniappan (7), but it was necessary in order to eliminate all the hypoglycaemic episodes while diazoxide was weaned off. The deceleration of weight gain with near complete resolution of the hypertrichosis are other important factors to consider. Potential side effects of sirolimus include mucositis, hyperlipidaemia, pneumonitis, severe infections and bone marrow suppression, which have been reported in adult studies and are reversible with dose reduction (8) . In our patient, her blood counts remained normal throughout the treatment and there was no increased frequency of infections after starting sirolimus. The side effects noted were transient oral ulcers and clinically insignificant elevations in the serum CK and ALT. Oral ulcers after administration of sirolimus can be minimized by rinsing the mouth with water or juice.
Hyperinsulinism often becomes milder over time with slow progressive β-cell apoptosis in patients with diffuse HH. Animal studies have also demonstrated that rapamycin (also known as sirolimus) can cause a 50% reduction in β-cell mass by increased apoptosis (9) . Since this patient's capillary glucose levels had been stable for 6 months and the long-term side effects of sirolimus are not known, sirolimus was gradually weaned off over 6 months. With this, the oral ulcers stopped appearing. The half-life of sirolimus is approximately 63 h and sirolimus should be eliminated from the body within 5 half-lives, or approximately 13.1 days. For this child, the capillary glucose levels were maintained >4 mmol/L, although she was recently hospitalized for a hypoglycaemic episode associated with severe viral gastroenteritis. Close monitoring will be necessary to ascertain if she can maintain long-term normoglycaemia without sirolimus.
In conclusion, sirolimus significantly improved this child's blood glucose levels, allowing cessation of diazoxide with resolution of hypertrichosis and prevention of excessive weight gain. This illustrates the utility of sirolimus in treating diffuse HH, which is not fully responsive to diazoxide, while avoiding the untoward side effects of diazoxide. While transient elevations in serum CK and ALT levels were noted in our patient, more studies into the long-term efficacy and safety of sirolimus are necessary.
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